Printer Friendly

ATL PLANS PMA FILING AND ECONOMIC OUTCOMES STUDY BASED ON BREAST ULTRASOUND CLINICAL TRIAL

 CHICAGO, Nov. 29 /PRNewswire/ -- Advanced Technology Laboratories, Inc. (ATL) (NASDAQ-NMS: ATLI) said today it plans to seek approval from the U.S. Food and Drug Administration (FDA) for the use of its High Definition(TM) Imaging technology for the differentiation of solid breast masses, based on the results of a recent clinical study.
 Kenneth Taylor, M.D., Ph.D., professor of diagnostic radiology at Yale University and one of the investigators in the ATL-sponsored study, presented the study findings today in Chicago at the 79th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA). Due to FDA regulations, the company is not at liberty to discuss the specific study results.
 "Today's presentation of clinical findings is a major milestone in an effort that began two years ago. We are pleased with the results of the study and the potential of High Definition Imaging (HDI(TM)) to positively affect patient outcomes and the cost of care," stated Dennis C. Fill, chairman and chief executive officer. "This exemplifies ATL's commitment to patient outcomes studies that measure the clinical utility of our technology."
 The company plans to submit a Premarket Approval Application (PMA) to the FDA for this new indication in December. If granted, the company believes this would be the first PMA ever issued for a diagnostic ultrasound instrument.
 The purpose of ATL's Multi-Center Study was to determine whether the use of advanced digital broadband (HDI) ultrasound technology could increase the ability of the physician to distinguish benign from malignant breast disease following mammography and thereby reduce the need for breast biopsy. In the United States, up to 80 percent of breast lesions are found to be benign after surgical or needle biopsy.
 ATL also said it is in the process of developing an economic outcomes study. The company plans to work with health economists to assess the clinical trial results in terms of the medical cost savings of this application of the HDI system.
 The ultrasound technology evaluated in the study, the High Definition Imaging System and the L10-5 Broadband Linear Array Scanhead, was introduced in April of 1991. Based on clinicians' positive responses to the technology and its exceptional ability to display fine detail, ATL began the international, 14-site study in September of the same year.
 ATL, with headquarters in Bothell, Wash., is a worldwide leader in the development, manufacture, distribution and service of diagnostic medical ultrasound systems. ATL stock is traded on the NASDAQ National Market System under the symbol ATLI.
 -0- 11/29/93
 /CONTACT: Anne Marie Bugge or Jane Hedberg of Advanced Technology Laboratories, 206-487-8077 or 206-487-7081/
 (ATLI)


CO: Advanced Technology Laboratories, Inc. ST: Illinois, Washington IN: MTC SU:

TW-MP -- NY028 -- 8215 11/29/93 11:04 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 29, 1993
Words:455
Previous Article:TELOR REPORTS DEVELOPMENT DECISIONS FOR ITS ANTI-GLAUCOMA PROGRAM
Next Article:LOTUS TO WORK TOGETHER WITH REVELATION TECHNOLOGIES TO PROVIDE ENHANCED GROUPWARE CAPABILITIES
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters